Quanterix Serum Nf-L Assay Powers Key Trial and Study Results Presented at ECTRIMS 2019
Presentations by leading researchers demonstrate promise and relevance of Neurofilament light chain (Nf-L) as a reliable disease biomarker for MS
Major Serum Nf-L highlights from ECTRIMS included:
Powering Drug Trials:
Novartisannounced that its Phase III ASCLEPIOS trials demonstrate the efficacy of ofatumumab in patients with relapsing MS. Nf-L using Simoa was used as a secondary endpoint and showed reductions after just three months of treatment.
Therapeutic Effectiveness: Several industry presentations on efficacy and comparative effectiveness of existing disease-modifying therapies in MS included data on Nf-L.
Rocheannounced results of retrospective analyses of its Phase III OPERA I, OPERA II and ORATORIO trials for patients with relapsing-remitting or primary progressive MS treated with Ocrevus, who saw serum Nf-L levels (measured with Simoa) lowered to those of healthy donors. These reductions in Nf-L were accompanied by significant reductions in wheelchair use and disease activity progression.
Revealing Biology of Disease: Several studies, including recently published data in the
Journal of American Medicine (JAMA) Neurologyprovided greater insights into the biology of MS, connection between inflammation and neurodegeneration, understanding the genetics of MS severity, and how additional Simoa assays such as GFAP can be combined with Nf-L for even greater insights. One study showed serum Nf-L levels rising six years before the onset of MS, suggesting a possible role for the test as an early marker of neuronal damage.
Moving from Research to the Clinic: Numerous studies were presented further strengthening the role of serum Nf-L as a prognostic and treatment monitoring tool in MS, and supporting future implementation for clinical use. Biogen released data generated in collaboration with
Siemens Healthineersusing Quanterix/UmanDiagnostics Nf-L antibodies to adapt the Simoa assay onto a routine analyzer platform, bringing promise to a future IVD assay.
“The research presented at ECTRIMS is critical to the MS community. The use cases of Nf-L as a valuable biomarker are growing rapidly,” said
According to the National
Data released from ECTRIMS indicated there were more than 9,000 participants in the conference from more than 100 countries, 1,316 posters, and 1,893 abstracts. Over the past several years, the medical and research community has witnessed mounting support for Nf-L as a reliable biomarker for MS prognosis and treatment monitoring, evidenced by the volume of scientific research validating its application for identifying neurogenerative conditions.
To learn more about Quanterix’ Nf-L assay, click here.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements regarding the completion of the proposed public offering. These statements are subject to various risks and uncertainties, actual results could differ materially from those projected and
Marissa Sweazy, 781-913-8036